Against material from bacteria (C07K16/12)

Human antibodies to clostridium difficile toxins // 2628305
FIELD: biotechnology.SUBSTANCE: completely human antibodies that bind either to toxin A, or to toxin B Clostridium difficile, or both to toxin A and toxin B. Formulations containing these antibodies and methods for their application are also described. The antibodies of the present invention are useful for neutralisation of toxins from C. difficile, thus providing agents for treatment of disease and symptoms associated with C. difficile infection, including an agent for treatment of diarrhea or pseudomembranous colitis caused by C. difficile. Antibodies may also limit the severity and/or duration of the underlying disease or limit the amount, duration and/or severity of disease relapse or exacerbation due to the presence of C. difficile.EFFECT: antibodies of this invention may also be suitable for infection diagnosis.34 cl, 5 dwg, 10 tbl, 11 ex

Antigen binding section (fab), including humanized fab, against botulinical neurotoxin c (versions), method to obtain fab using yeast, method and set for botulinical neurotoxin c detection // 2623157
FIELD: biotechnology.SUBSTANCE: antigen-binding fragments (Fab) are described that selectively bind to botulinum neurotoxin C, in particular humanized Fab. Yeast cells producing the said humanized Fab are presented. A method for producing the described humanized Fab is proposed. A method for botulinum neurotoxin C detection and a kit for botulinum neurotoxin C detection is also proposed.EFFECT: invention allows to obtain reagents for botulinum neurotoxin C detection, which have a high binding specificity to the said neurotoxin.9 cl, 12 dwg, 6 tbl, 9 ex

Clone of cultivated hybrid animal cells mus musculus l.h-24-producer of monoclonal antibodies specific to staphylococcal enterotoxin h (seh) // 2616289
FIELD: biotechnology.SUBSTANCE: invention relates to microbiology and biotechnology, namely to hybridoma technology. Invention represents cultivated hybrid H-24 cell clone producing in environment of cell culture and abdominal cavity of syngeneic animals monoclonal antibody (MA) H-24 to SEH. Clone is produced by fusion of cells of mouse myeloma SP-2/0 with popliteal lymph node cells of BALB/c mice immunized with SEH subcutaneously. Fusing agent is polyethylene glycol with molecular weight of 1,500. Hybridoma selection has been performed on medium DMEM with bovine foetal serum and addition of hypoxantine-aminopterin-thymidine. Hybridoma synthesizes MA, specifically interacting with SEH. Antibody titre in culture liquid reaches no less than 1:10,000 1:20,000, in ascitic one it is no less than 1:1,000,000. Antibodies can be used for designing immunochemical SEH detection systems. In version of sandwich ELISA using biotinylated MA detection of H-18 and streptavidin peroxidase SEH is detected in concentration range from 0.2 (minimum limit of determination) up to 3 ng/ml.EFFECT: invention can be used for detection of staphylococcal enterotoxin H (SEH).1 cl, 3 dwg, 1 tbl, 7 ex

Humanised antibodies specific for hsp65-derived peptide-6, methods and uses thereof // 2596925
FIELD: pharmaceutics.SUBSTANCE: group of inventions relates to humanised antibodies and their fragments, which specifically bind a polypeptide containing peptide-6, denoted by SEQ ID NO: 15, which is a peptide derived from HSP65. More specifically invention relates to compositions, methods and use thereof for treating immune disorders. Further, group of inventions includes combined compositions and kit combining humanised antibodies and at least one anti-inflammatory agent.EFFECT: use of humanised antibodies according to invention enables to modulate balance of Th1/Th2 cytokines.29 cl, 31 dwg, 13 tbl, 25 ex

Antibody against lipoarabinomannan and immunoassay of infections caused by acid-fast bacilli, using antibody // 2588480
FIELD: biochemistry.SUBSTANCE: described is monoclonal antibody which specifically binds to lipoarabinomannan of acid-fast bacilli, particularly with lipoarabinomannan of tuberculosis bacilli. Described antibody is monoclonal antibody containing variable heavy and light chain variable region, connected through linker. Variable heavy chain contains CDR1-CDR3 shown in (a)-(c), and light chain contains CDR1-CDR3 shown in (d)-(f):(a) heavy chain CDR1, consisting of amino acid sequence SEQ ID No:1,(b) heavy chain CDR2 consisting of amino acid sequence SEQ ID No:2,(c) heavy chain CDR3 consisting of amino acid sequence SEQ ID No:3,(d) light chain CDR1, consisting of amino acid sequence SEQ ID No:4,(e) light chain CDR2 consisting of amino acid sequence SEQ ID No:5, and(f) light chain CDR3 consisting of amino acid sequence SEQ ID No:6. Invention also describes reagent kit and device containing described antibody.EFFECT: invention extends range of products for detecting of mycobacteria.18 cl, 19 dwg, 5 tbl, 12 ex

Complex of recombinant polypeptides with protective properties in relation to streptococcus agalactiae and streptococcus pyogenes // 2587627
FIELD: biology.SUBSTANCE: invention relates to microbiology and molecular genetics. Disclosed is a complex of recombinant polypeptides for prevention and treatment of bacterial infections caused by Streptococcus agalactiae and/or Streptococcus pyogenes. Complex comprises in equal portions recombinant polypeptides P6, recScaAB, StV, RV1 and Csp1a having amino acid sequence SEQ ID No: 1-5, respectively. Complex has no toxic action on body in mammals. Causes a synergetic effect during synthesis of specific antibodies anti-P6, anti-recScaAB, anti-StV, anti-PB1 and anti-Csp1a, which have protective action against Streptococcus agalactiae and Streptococcus pyogenes, shows a synergetic effect in relation to Streptococcus agalactiae.EFFECT: prevention and treatment of bacterial infections caused by Streptococcus agalactiae and/or Streptococcus pyogenes.1 cl, 5 tbl, 19 ex, 21 dwg

Polypeptide of anti-cyanobacterial recombinant antibody, its gene and method of its preparing // 2586482
FIELD: biotechnology.SUBSTANCE: polypeptide of an antibody mimetic is disclosed, having the function of detection and binding with cyanobacteria, which amino acid sequence is revealed in SEQ ID NO. 3. Also a gene is disclosed, which encodes a polypeptide of an antibody mimetic. A polypeptide having a function of anti-cyanobacterial recombinant antibody is described, constructed by coupling the said polypeptide of an antibody mimetic with the function of detection and binding with cyanobacteria with the C-terminus of colicin polypeptide, where the said colicin is selected from the colicin E1, Ia, Ib, A, B or N. Also the corresponding gene and the recombinant expression vector containing such a gene are described. The application of this polypeptide with water eutrophication is described.EFFECT: increased efficiency of the compound application.10 cl, 11 dwg, 1 tbl, 5 ex

Novel peptides and methods for production thereof // 2583579
FIELD: biology.SUBSTANCE: invention relates to biology and genetic engineering. Disclosed is an isolated peptide for therapeutic purposes, containing a sequence at least 95% identical to SEQ ID NO: 4 (GG00444), or its fragment or variant, capable of binding with human bowel mucus, as well as fimbriated structure comprising same, food product, pharmaceutical composition, polynucleotide, expression vector, host cell, gene cluster, antibody, method of treatment and method of screening probiotic bacterial strains.EFFECT: treatment of intestinal diseases.33 cl, 11 dwg, 2 tbl, 11 ex

Neurotoxins that display reduced biological activity // 2582266
FIELD: bioengineering.SUBSTANCE: claimed polypeptide includes the signal of degradation in the light strand wherein the said reduced duration of a biological effect is the reduced duration of the biological effect as compared with the appropriate unmodified polypeptide neurotoxin and wherein the said degradation signal is selected from the group consisting of the following elements, i.e. internally or terminally introduced PEST motive, internally or terminally introduced motive of identification by an E3 ligase. A polynucleotide contains the series of a nucleic acid selected from the group consisting of the following elements, i.e. the series of nucleic acid SEQ ID NO: 1, 3, 5, 7, 9, 11, 13 or 15.EFFECT: production of the polypeptide clostridial neurotoxin of the reduced duration of the biological effect on the subject.16 cl, 2 tbl

ethod of detection of microorganisms belonging to species of mycoplasma pneumoniae mind and/or mycoplasma genitalium // 2575075
FIELD: biotechnology.SUBSTANCE: method and a kit for detection and rapid and specific diagnostics of infections of Mycoplasma pneumoniae and/or Mycoplasma genitalium is described. The indicator is applied as DnaK Mycoplasma pneumoniae or Mycoplasma genitalium.EFFECT: possibility of application in medicine.7 cl, 10 dwg, 11 tbl, 8 ex

Anti-pbp2a protein monoclonal antibodies and homologous sequences for treating bacterial infection and immunodiagnosis of firmicutes bacteria // 2575070
FIELD: chemistry.SUBSTANCE: what is presented is a recovered monoclonal antibody, which binds to PBP2a or PBP5 protein. The above antibody contains a heavy chain variable region having CDR1 region, which includes SEQ ID NO: 12, CDR2 region, which includes SEQ ID NO: 13, CDR3 region, which includes SEQ ID NO: 14, and a light chain variable region having CDR1 region, which includes SEQ ID NO: 6, CDR2 region, which includes SEQ ID NO: 7, CDR3 region, which includes SEQ ID NO: 8. What is also presented is a pharmaceutical composition containing the above antibody.EFFECT: group of inventions has immunising action on an infection caused by bacteria possessing PBP2a or PBP5 protein.4 cl, 20 dwg, 3 tbl, 4 ex

Devices and method to produce highly cleaned neurotoxins // 2571212
FIELD: bioengineering.SUBSTANCE: polyclonal or monoclonal antibody is suggested, it specifically links epitope out of TKSLDKGYNK peptides of Clostridium neurotoxins, and is produced by use of oligopeptide with said epitope. Method of production of antibody specific for proteolytic unprocessed and/or partially processed botulinic neurotoxins type A. Polyclonal protective serum produced by immunization by TKSLDKGYNKA immunogen is mixed with said peptide. The produced complex of peptide and antibodies are removed from protective serum. The antibody is separated from the said complex. Polyclonal antibody produced by said method and producing complex with TKSLDKGYNKA is described. Use of antibodies is suggested for separation or determination of proteolytically partially processed and/or unprocessed polypeptide. Method of production of proteolytically processed polypeptide of botulinic neurotoxins type A is suggested. Solution with mixture of proteolytically processed, partially processed and/or unprocessed polypeptide botulinic neurotoxins type A is mixed with antibody with creation of complexes of antibodies with proteolytically partially processed and/or unprocessed polypeptide. The produced complex of peptide and antibody is removed from solution. Method of production of medicament is described, under it the method of production of proteolytically processed polypeptide botulinic neurotoxins type A is used with further formation of said solution as the medicament.EFFECT: separation of proteolytically partially processed or unprocessed polypeptide botulinic neurotoxins type A, this can be used to produce the medicinal compositions of botulinic neurotoxins type A.16 cl, 3 dwg, 2 tbl, 2 ex

Recombinant pseudo adenoviral particle producing modified nanoantibodies recognising mycoplasm mhominis, based pharmaceutical composition and method for using it for mycoplasmosis therapy // 2562158
FIELD: medicine, pharmaceutics.SUBSTANCE: present invention refers to molecular immunology, biotechnology and medicine. A pre-modified sequence of an antibody gene is the nucleotide sequence SEQ ID 1. The created recombinant pseudo adenoviral particle activates a complement system of the mammalian immune system. The pharmaceutical composition represents the recombinant pseudo adenoviral particles according to the declared invention, and a pharmaceutically acceptable carrier; when administered into a mammalian organism, it activates the complement system and suppresses mycoplasm M. hominis. A method for mycoplasm M. hominis therapy is implemented by administering a therapeutically effective amount of the created pharmaceutical composition into a mammal in need thereof. The pharmaceutical composition is administered by intravenous injections.EFFECT: created is the recombinant pseudo adenoviral particle based on human being adenovirus genome of serotype 5 containing an expressing cassette with gene insertion of a modified chimeric nanoantibody binding to mycoplasm M hominis, a nucleotide sequence of which is pre-modified by attaching the effector Fc-fragment of immunoglobulin G.5 cl, 6 dwg, 2 tbl, 6 ex

Antibodies or their fragments, aimed against staphylococcus aureus epitope // 2560415
FIELD: medicine.SUBSTANCE: invention relates to field of biochemistry, in particular to antibody or its functional fragment, aimed against Staphylococcus aureus epitope, as well as to their application for Staphylococcus aureus detection. Disclosed is cell line of hybridoma, which produces said antibody, where cell line of hybridoma is cell line, deposited in DSMZ under accession number DSM ACC2987. Invention also relates to method of treatment or prevention, which contains introduction of said antibody or its functional fragment to human or animal, where treatment is treatment of infection in human or animal, where infection is caused by Staphylococcus aureus, and where prevention is prevention of such disease, caused by Staphylococcus aureus.EFFECT: invention makes it possible to effectively treat human infection, caused by Staphylococcus aureus.20 cl, 7 dwg, 1 tbl
Strain of f26 of constant monoclonal antibody line of cells of mus musculus mouse - producer of monoclonal antibodies to oligopolysaccharide (ops) antigen b abortus // 2560260
FIELD: biotechnologies.SUBSTANCE: invention represents a strain of F26 of the constant monoclonal antibody line of cells of Mus. musculus mouse - the producer of monoclonal antibodies of mouse an oligopolysaccharide (OPS) antigen B. abortus deposited in the Specialised Collection of the transplantable somatic cell cultures of farm and game animals of Russian Collection of Cell Cultures (FGA RAA) RRIEV at the Public Scientific Institution "Ya.R. Kovalenko All-Russian Research Institute of Experimental Veterinary Science of Russian Agricultural Academy" (PSI RRIEV of Russian Agricultural Academy), Moscow at No. 90.EFFECT: invention allows to perform high production of monoclonal antibodies.4 ex

Components of enterococcal cell walls and their antibacterial application // 2559543
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to the field of biotechnology, microbiology and immunology. Described is a polysaccharide of an enterococcal cell wall. The polysaccharide can be applied as an antigen for obtaining vaccines. Also disclosed are: antibody to the said polysaccharide and pharmaceutical compositions for the prevention and therapy of a bacterial infection.EFFECT: claimed group of inventions can be used in medicine.8 cl, 6 dwg

External cow lipopolysaccharide epitope h. pylori // 2558257
FIELD: chemistry.SUBSTANCE: present invention relates to biotechnology and provides a α1,6-glucan-containing compound of Helicobacter pylori. The present invention also discloses a conjugate for inducing immune response against H.pylori, which contains said compound conjugated with a carrier protein. The present invention also discloses an immunogenic composition, use of said composition and a method of inducing immune response against H.pylori using said composition. The present invention also discloses immune serum for neutralising H.pylori in mammals, which is obtained by immunising said mammal with an immunogenic composition containing said immunogenic composition. The present invention discloses an antibody which recognises said α1,6-glucan-containing compound of H.pylori, use of said antibody and a method of inducing complement-mediated bacteriolysis of H.pylori strains which express α1,6-glucan using said antibody.EFFECT: invention improves the effectiveness of immunogenic compositions against Hpylori.27 cl, 8 dwg, 21 tbl, 11 ex

Strain of cultivated hybrid animal cells mus musculus bpm vd-9 - producer of monoclonal antibody 5c2/f10/c9 to antigen 200 kda melioidosis agent // 2556803
FIELD: biotechnology.SUBSTANCE: strain of cultivated hybrid animal cells Mus musculus Bpm Vd-9 is proposed, deposited in State collection of pathogenic microorganisms and cell cultures "SCPM-OBOLENSK" under the number H-31. This strain is a producer of monoclonal antibody 5C2/F10/C9 to glycoprotein 200 kDa of melioidosis agent. The antibody produced by cells of the strain according to the present invention may find application as an anti-idiotope ("detecting antibody"), labelled with horseradish peroxidase as a part of the test system for detection of glycoprotein 200 kDa B. pseudomallei in the test samples.EFFECT: improvement of properties.1 dwg, 2 tbl, 5 ex
Strain of cultivated hybrid cells of animal mus musculus bpm vd-8 - producer of monoclonal antibody 3c6/a9 to antigen 200 kda of pseudocholera activator // 2555544
FIELD: biotechnologies.SUBSTANCE: strain of cultivated hybrid cells of animal Mus musculus Bpm Vd-8 deposited in the State Collection of pathogenic microorganisms and cellular cultures "GKPM-OBOLENSK" under the number N-30 is offered. This strain is a producer of the monoclonal antibody 3C6/A9 to glycoprotein 200 kDa of pseudocholera activator.EFFECT: antibody produced by strain cells according to the present invention can be used as one of components of the mix of the first order antibodies adsorbed at the solid phase and which perform the function of capture of anti-gene as a part of the test system intended for detection of anti-genes of pathogenic burkholderia.2 tbl, 5 ex

Non-lipidised variants of neisseria meningitidis orf2086 antigens // 2546873
FIELD: medicine, pharmaceutics.SUBSTANCE: group of inventions refers to biochemistry, particularly to an immunogenic composition, which induces cross-reactive bacterial antibodies to a number of strains Neisseria meningitidis serotype B. As an active ingredient, the immunogenic composition contains variants of the non-lipidised polypeptide ORF2086non-functionalised by pyroracemic acid and consisting of an amino acid sequence specified in a group of SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO: 20 and SEQ ID NO: 21, wherein the polypeptide contains N-terminal Cys deletion as compared to the existing non-lipidised wild-type polypeptide ORF2086. What is also disclosed is a plasmid, which expresses the non-lipidised polypeptide ORF2086 non-functionalised by pyroracemic acid. What is also disclosed is a method for producing bactericidal antibodies specific to ORF2086 of the sub-family B of the serogroup Neisseria meningitidis in mammals.What is also disclosed is a method for producing the non-lipidised polypeptide ORF2086 non-functionalised by pyroracemic acid.EFFECT: invention enables inducing the cross-reactive bacterial antibodies to Neisseria meningitidis serotype B.32 cl, 8 dwg, 14 tbl, 13 ex

Prophylaxis, treatment and diagnostics of infection caused by p.gingivalis bacteria // 2535898
FIELD: biotechnologies.SUBSTANCE: invention describes a composition for induction of immune response against P. gingivalis, which contains an effective amount of one of the above chimeric or hybrid proteins, a prophylaxis method of a state or a disease related to P. Gingivalis, and a method for reduction of incidence or severity of the state or disease related to P. gingivalis with their application. Besides, the invention describes use of the above chimeric or hybrid proteins for determination of antibodies to P. Gingivalis in a biological specimen.EFFECT: invention allows effective induction of immune response against the specified etiologic agent.16 cl, 7 dwg, 4 tbl, 22 ex

onoclonal human antibody against alpha-toxine from s. aureus and its application in treatment or prevention of abscess formation // 2529946
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to biochemistry, in particular to a monoclonal human antibody, specific to alpha-toxin of S. aureus. The claimed invention additionally relates to pharmaceutical compositions for treatment of prevention of the abscess formation in an organ, which contains at least one antibody or one nucleic acid, which codes the said antibody.EFFECT: invention makes it possible to extend an assortment of antibodies, specific to alpha-toxin of S aureus.23 cl, 7 dwg, 4 tbl, 6 ex

Vaccines and vaccine ingredients for microbial cell inhibition // 2528854
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to biochemistry, particularly to a recovered polypeptide which is a biological target for methane-producing cell inhibition, as well as to a recovered polynucleotide which codes this polypeptide. There are disclosed expression vector and cloning vector containing this polynucleotide, and host cells containing the above expression vector. There are described conjugated molecules or fused molecule for methane-producing cell inhibition, as well as antibody or its functional fragment which binds to the above polypeptide. The invention also covers a pharmaceutical composition and methods for inhibiting and identifying the methane-producing cell with the use of the above conjugated molecule or fused molecule and the antibody or its fragment.EFFECT: invention enables inhibiting the methane-producing cell effectively.19 cl, 9 dwg, 6 ex

Immunogenic composition applicable for staphylococcus vaccination // 2521501
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to immunology, molecular biology and genetic engineering. There are presented an immunogenic composition containing a mixture of staphylococcal proteins, and comprising a staphylococcal protein binding an extracellular component, and a staphylococcal transport protein, or the staphylococcal protein binding the extracellular component, and a staphylococcal virulence regulator or a toxin, or the staphylococcal transport protein and the staphylococcal virulence regulator or the toxin. There are also presented vaccines, methods of treating, using and methods for preparing a staphylococcus vaccine.EFFECT: invention may be used in medicine for treating and preventing a staphylococcal infection.23 cl, 8 tbl, 7 dwg, 8 ex

Immunologic analyses of botulinum toxin serotype a activity // 2491293
FIELD: chemistry.SUBSTANCE: invention discloses composition for production of antibodies SNAP-25, capable of binding with epitope, which contains C-end (carboxylic) on residue P1 of cleaved bond of cleavage site BoNT/A of SNAP-25 cleavage product, which contains carrier, flexible linker, containing at least three amino acids, and SNAP-25 antigen, for which amino acid sequence is given. Described are versions of antibodies α-SNAP-25 with said capability and their application in method of detecting BoNT/A activity with application of cells from stable cell line, sensitive to BoNT/A intoxication, and method of determining immunoresistance to BoNT/A in mammal with application of tested animal sample and cells of stable cell lime, whose cells are sensitive to BoNT/A intoxication.EFFECT: application of invention ensures reliability, simplicity and makes it possible to exclude necessity of animal tests from botulinum toxin analyses.15 cl, 11 dwg, 14 tbl, 12 ex

Nanoantibodies binding chlamydia trachomatis antigen, method of inhibiting infection caused by chlamydia trachomatis // 2487724
FIELD: medicine.SUBSTANCE: present invention refers to biotechnology and medicine. There are presented versions (aCt1 and aCt2) of one-domain antibodies specifically binding the Chlamydia trachomatis antigen. There are described versions of the method of inhibiting an infection caused by Chlamydia wherein the method involves the preparation of elementary bodies C.trachomatis by a therapeutically effective amount of the nanoantibody aCt1 or aCt2 before being attached to infected target cells.EFFECT: use of the invention provides the antibodies to detect and block the infections Chlamydia trachomatis that can find application in medicine.6 cl, 4 dwg, 5 ex

Nanoantibodies amh1, amh2 binding antigen of mycoplasma homints, method of producing them, method of treating mycoplasma hominis infection // 2484095
FIELD: medicine.SUBSTANCE: there are presented antibodies specifically binding the lipid-associated antigen of M.hominis with the characterised amino acid and nucleotide sequences, as well as a method of treating a Mycoplasma M.hominis infection involving administering to said mammal a therapeutically effective amount of the nanoantibodies.EFFECT: invention can find further application in treating the mycoplasma infection.4 cl, 2 tbl, 6 ex, 5 dwg
ethod for preparing anthrax diagnostic serum and diagnostic set // 2478647
FIELD: medicine, pharmaceutics.SUBSTANCE: invention discloses a method for preparing an anthrax diagnostic serum by hyperimmunisation of ox producers with an antigen of the strain Bacillus anthracis M-71. Hyperimmunisation is conducted in increasing doses: first subcutaneous introduction of the antigen 100-120 mln microbial cells together with saponin 2.5-3 mcg; 12-14 days later, the antigen is introduced intracutaneously in a dose of 2.5-3.0 bln microbial cells together with saponin 2.5-3 mcg; 6-7 days later, every 3-4 days, the antigen is introduced intravenously 12-14 times in increasing doses 10.0 to 210 bln. microbial cells. It is followed by blood sampling, keeping at temperature 37-38°C for 2-3 hours, placing in a fridge at 2-8°C for 3-5 days, separating serum. The prepared serum is preserved in 5-7% carbolic acid in isotonic solution in ratio (9-10):1 respectively. The ready serum is sterile and has an AR titre min. 1:1000, a CFT titre min. 1:20. A diagnostic set for anthrax diagnosis comprises the antigen of the strain Bacillus anthracis M-71, the anthrax diagnostic serum and healthy bovine's native serum.EFFECT: invention provides higher specific activity of the serum and diagnostic effectiveness for an anthrax agent.5 cl, 1 tbl, 3 ex

ulti-component immunogenic composition for preventing dosease, caused by β-hemolytic streptoccoci (bhs) // 2478396
FIELD: medicine, pharmaceutics.SUBSTANCE: invention discloses a number of polynucleotides and polypeptides β-hemolytic streptococci, in particular polypeptides and polynucleotides of Streptococcus pyogenes, and based on them immunogenic compositions, used for prevention or reduction of symptoms of colonisation or infection, caused by β-hemolytic streptococci. Immunogenic composition (versions) contains mixture of two or more polypeptides, encoded by sequence of nucleic acid (NA), which has, at least, 90% identity of sequence of NA, selected from group, consisting of peptidase C5a (SCP), open reading frame (OPC)554, OPC 1218, OPC 1358 and OPC 2459. One of versions of immunogenic composition contains polypeptide SCP, polypeptide peptidylpropylisomerase and, at least, one other polypeptide. Also disclosed are methods of protecting susceptible mammal against colonisation or infection, caused by β-hemolytic streptococcus, by immunisation of immunogenic composition by invention.EFFECT: invention provides immunogenic compositions and methods for prevention or reduction of symptoms of infections, caused by β-hemolytic streptococci of group A, B, C and G, as well as ensures immunity to wide spectrum of bacteria BHS.41 cl, 16 dwg, 2 tbl, 3 ex

Clostridial toxin netb // 2474587
FIELD: medicine.SUBSTANCE: invention discloses a purified and/recombinant antigen polypeptide possessing toxin activity, recovered from Clostridium perfringens with specified amino acid sequence. The invention discloses the recovered or recombinant polynucleotide coding such polypeptide, an expression vector and a host cell expressing the polypeptide. The invention discloses a method for preparing the polypeptide, an antibody specifically bound with the polypeptide, immunogenic compositions and vaccines containing the given polypeptide or a polynucleotide thereby providing a specifically immune response to the polypeptide. There are disclosed a method for inducing the immune response, a method of determining the fact whether an individual has been exposed to a pathogen (versions), a method of screening, an agonist or an antagonist modulating activity of the polypeptide, a method of animal vaccination, e.g. hens for inducing active immunity, as well as passive immunity in hen off-springs which becomes less sensitive to clostridial diseases. What is disclosed is a transgenic plant containing the exogenous polynucleotide coding the polypeptide under the invention, applicable for animal feeding.EFFECT: polypeptide is used as an ingredient of a forage or a beverage for preventing a disease caused by bacteria expressing the polypeptide under the invention.39 cl, 8 dwg, 6 tbl, 11 ex

Hybrid cell strain of mus musculus 13f8 animals - producer of monoclonal antibodies specific to capsular f1 antigen yersinia pestis // 2460788
FIELD: medicine.SUBSTANCE: hybrid cultured cell strain of the animals Mus museums 13F8 is produced by immunisation of Balb/c mice. The mice are immunised by four introductions of the recombinant antigen preparation F1 100 mcg/mouse. The third post-immunisation day is followed by splenocyte hybridisation of the immunised mice (1x108 cells) and mice myeloma cells P3-X63 Ag/8-653 (1×107cells). Polyethylene glycol (Sigma, the USA) is used as a fusion agent. The hybridisation is followed by hybridoma selection, screening, cloning and cryopreservation. Hybridoma is deposited in the State Collection of Pathogens and Cell Cultures of GKPM-Obolensk, No. N-18.EFFECT: hybrid cultured cell strain producing monoclonal antibodies is applicable for constructing the based plague agent test systems.7 dwg, 4 tbl, 8 ex

Neisseria meningitidis polypeptides // 2450019
FIELD: medicine.SUBSTANCE: polypeptide (versions) immunogenic with respect to meningococcal infections contains: an amino acid sequence at least 90 % identical to a sequence presented in the description (SEQ ID NO: 32), or said amino acid sequence, or a fragment of 80 sequenced amino acids of said sequence. What is described is an antibody which contacts with the polypeptide under the invention and which may be used as a drug. What is described is nucleic acid of the preset structure which codes the polypeptide or its versions and which may be used for treating or preventing a disease and/or an infection caused by Neisseria meningitides. The invention provides additional polypeptides applicable in advanced vaccines for preventing and/or treating meningococcal meningitis. The peptides can also find application in diagnosing of the disease and as targets of antibiotics.EFFECT: higher clinical effectiveness for meningococcal meningitis.19 cl, 2 tbl

Drug preparation for treating infectious diseases accompanied by neurotoxic disorders, and method of treating infectious diseases accompanied by neurotoxic disorders // 2446821
FIELD: medicine, pharmaceutics.SUBSTANCE: drug preparation for treating infectious diseases accompanied by neurotoxic disorders including neuroinfectious and neurodegenerative diseases is presented in the form of a pharmaceutical composition and contains an activated potentiated form of human gamma interferon (IFN-γ) antibodies and an activated potentiated form of brain-specific S-100 antibodies. The pharmaceutical composition is presented in a solid dosage form - in the form of granules. As pharmaceutically acceptable additives, it contains lactose, microcrystalline cellulose and magnesium stearate, and each of the components of very-low-dose affinity purified antibodies are used in the form of a mixture of various, preferentially homoeopathic dilutions 1/100. A method of treating and preventing infectious diseases accompanied by neurotoxic disorders involves the introduction into a body of the activated potentiated form of IFN-γ antibodies, and an enhancing agent in the form of the activated potentiated form of very-low-dose affinity purified brain-specific S-100 antibodies.EFFECT: use of the invention enables enhanced immune response at height of the disease, ensures effective rehabilitation and prevents recurrences of the disease.14 cl, 4 dwg, 1 tbl, 2 ex

Genes and proteins of brachyspira hyodysenteriae and use thereof // 2440369
FIELD: chemistry.SUBSTANCE: invention describes novel polynucleotide and amino acid sequences of Brachyspira hyodysenteriae, which can be used to diagnose diseases in animals, caused by B. hyodysenteriae, to treat or prevent diseases associated with infection with B. hyodysenteriae. The invention describes a cell containing a plasmid containing a polynucleotide, for treating and preventing a disease associated with infection of an animal with B. Hyodysenteriae. The invention describes immunogenic and vaccine compositions for generating immune response in an animal, which contain a polypeptide, a polynucleotide, a cell or a plasmid for treating or preventing infection of animals by B. hyodysenteriae, as well as sets of instruments for diagnosis which contain a monoclonal antibody, capable of biding the disclosed polypeptide or a polypeptide or polynucleotide. The invention enables to successfully diagnose diseases caused by B. hyodysenteriae, prevent or treat animals infected with B. hyodysenteriae. The sequences described herein can be used for diagnosis and therapeutic and/or preventive treatment of animals from diseases caused by other types of Brachyspira, including B. intermedia, B. suantatina, B. alvinipulli, B. aalborgi, B. innocens, B. murdochii and B. pilosicoli.EFFECT: high efficiency of using the composition.39 cl, 4 tbl

Strain of hybrid cultivated cells of animal mus musculur 1e6-producer of monoclonal antibodies, specific to bacillus anthracis spores // 2439148
FIELD: medicine.SUBSTANCE: strain of hybridioma is obtained by immunization of mice of line BALB/c. Mice are immunised by conventional method by double with thirty day exposition subcutaneous introduction of inactivated spores of B. Anthracis strain "СТИ-1". On the third day after last buster-injection carried out is hybridisation of splenocytes of immune mice (1×108 cells) with cells of mouse myeloma P3-X63 Ag/8-653 (1×107 cells), using for fusion polyethylene glycol (Sigma, USA). After hybridisation carried out are selection, screening, cloning and cryopreservation of hybridoma. Obtained hybridoma is deposited in collection of microorganisms of FSSE SRC AMB under number H10. Invention relates to biotechnology and can be used for obtaining monoclonal antibodies (MCA) to spores Bacillus anthracis. Strain productivity is 20-50 mcg/ml of monoclonal antibodies (MCAla in ascitic liquid- 5-10 mg/ml. Hybridoma produces MCA, related to IgGl subclass of mouse immunoglobulins and spores specific to Bac.anthracis.EFFECT: increase of strain productivity.7 dwg, 2 tbl, 9 ex

Bioanalysis and peptides used in said bioanalysis // 2439080
FIELD: chemistry.SUBSTANCE: invention discloses peptides for detecting Mycobacterium tuberculosis, which consist of less than 18 amino acids and are capable of binding with the antibody against GRDIKVQFQSGGNNSPAV peptide (all sequences are given in a list of sequences). One of the peptides contains an NSPAX sequence, where X denotes methionine. More preferably, the peptides contain an NNSPAV sequence or have the type SGGNNSPAX, where X denotes methionine, leucine, alanine or valine. The invention describes a nucleotide sequence which codes the disclosed peptides, as well as an antibody or fragment thereof, capable of binding with said peptide. The invention discloses methods of detecting M.tuberculosis, involving ELISA substitutive analysis of a sample using a peptide capable of binding with the antibody against GRDIKVQFQSGGNNSPAV peptide or using the antidody.EFFECT: use of the invention simplifies tests to determine anti-tuberculosis antibodies in a population owing to the artificially modified peptide sequences of T-cell epitope Ag85B M tuberculosis.27 cl, 5 dwg

Nontypeable haemophilus influenzae polypeptides // 2432357
FIELD: medicine.SUBSTANCE: there are described polypeptides eliciting an immune response on H.influenzae. There is offered an antibody selectively binding specified polypeptides. The invention also concerns an immunogenic composition containing the described polypeptides.EFFECT: invention can be used in medicine for treating or preventing a disease or an infection caused by Hinfluenzae, such as otitis media.9 cl, 3 tbl

Immunogenic composition for use in vaccination against staphylococci // 2419628
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to biotechnology. Immunogenic composition is described comprising an effective amount of a combination of at least two different proteins or their immunogenic fragments selected from at least two groups of proteins or immunogenic fragments selected from the following groups: group (a): at least one staphylococcal protein binding an extracellular component, or its immunogenic fragment; group (b): at least one staphylococcal transport protein or its immunogenic fragment; group (c): at least one staphylococcal regulator of virulence, toxin or its immunogenic fragment, wherein at least one protein or an immunogenic fragment is selected from the group (a), and at least one protein or immunogenic fragment is selected from the group (b). A vaccine against staphylococcal infection is proposed, which comprises an effective amount of the immunogenic composition described. Also the method to obtain the vaccine is offered.EFFECT: method for preventing or treating staphylococcal infection is proposed, comprising the introduction of the proposed vaccine, as well as method of producing immunoglobulin, comprising the steps of immunisation of the recipient by the proposed vaccine.17 cl, 7 dwg, 8 tbl, 8 ex

Animal mus musculus hybrid cell clone l-producer of monoclonal cholera toxin antibodies // 2401301
FIELD: medicine.SUBSTANCE: there is produced a new CT-F5/H3 hybrid cell clone producing monoclonal cholera toxin antibody (MCAB) in the environment of cell culture and abdominal cavity of syngeneic animals. The clone is produced by the fusion of mouse myeloma SP-2/0 cells with popliteal lymph node cells of BALB/c mice immunised with a commercial preparation of cholera toxin (SIGMA) in posterior pads. A fusing agent is polyethylene glycol of molecular weight 4000. Hybridoma selection has been performed on Dulbecco modified Eagle's medium with bovine foetal serum and hypoxantine-aminopterin-thymidine added. Hybridoma synthesises MCAB specifically interacting with cholera toxin and not interacting with thermolabile E.coli toxin. The antibody titre reaches 1:20000 1:40000 in the cultural fluid, 1:4000000 in ascitic.EFFECT: antibodies can be used for designing immunobiological systems of cholera toxin detection exceeding available analogues in sensitivity.2 dwg, 4 ex

Animal mus musculus hybrid cell clone l-producer of monoclonal cholera toxin antibodies // 2401300
FIELD: medicine.SUBSTANCE: there is produced a new CT-E6/E10 hybrid cell clone producing monoclonal cholera toxin antibody in the environment of cell culture and abdominal cavity of syngeneic animals. The clone is produced by the fusion of mouse myeloma SP-2/0 cells with popliteal lymph node cells of BALB/c mice immunised with a commercial preparation of cholera toxin (SIGMA) in posterior pads. A fusing agent is polyethylene glycol of molecular weight 4000. Hybridoma selection has been performed on Dulbecco modified Eagle's medium with bovine foetal serum and hypoxantine-aminopterin-thymidine added. Hybridoma synthesises monoclonal antibodies specifically interacting with cholera toxin and not interacting with thermolabile E.coli toxin. The antibody titre reaches 1:10000 in the cultural fluid, 1:1000000 in ascitic.EFFECT: produced antibodies exceeds the analogues available in sensitivity.2 dwg, 4 ex

ethod of diagnosing lawsonia intracellularis // 2400758
FIELD: medicine.SUBSTANCE: essence of invention includes contact of liquid sample, taken from mammal organism, with one or several monoclonal antibodies to Lawsonia intracellularis antigen, secreted by cell lines of ECACC hybridomes, which have registration numbers. Invention also includes diagnostic test-kit, containing antibodies specific for Lawsonia intracellularis.EFFECT: increased specificity of antigen detection.11 cl, 5 ex, 5 dwg

Concerned sequences linkage method // 2392324
FIELD: medicine.SUBSTANCE: method facilitates linkage of sequences, coding immunoglobulin variable regions, T-cells receptors or B-cells receptors. Method is instrument of higher effectivity for making sequence data libraries. Capability of multiple RT-PCR with chain extension by interruption with employment of matrix, derived from single cell, provides highly effective creation of sister pairs libraries.EFFECT: method is effective for linkage of two or few nucleotide sequences, coding domens or subunits of heteromeric protein as a result of single reaction performance.51 cl, 25 dwg, 27 tbl, 14 ex

Treatment of bacterial infections // 2377251
FIELD: pharmacology.SUBSTANCE: invention concerns biotechnology. There is described application of antibody to acetyl-CoA-acetyltransferase or its antigen-binding fragment in manufacturing of a medical product for treatment or prevention of the infection caused by Clostridium difficile and Enterococcus faecalis, faecium is described. There is disclosed combined preparation for treatment of the infection caused by Clostridium difficile containing (i) antibody to acetyl-CoA-acetyltransferase or its antigen-binding fragment; and (ii) at least one antibiotic from the group consisting of gentamycin, vancomycin and metronidazole. There is presented inhibitor of acetyl-CoA-acetyltransferase representing antibody or its antigen-binding fragment, containing at least one component of the group consisting of (i) complementarity determining regions (CDR) of 1-3 VH-chain; and (ii) complementarity determining regions (CDR) of 3 VL-chain. There is described method of treating the infection caused by Clostridium difficile, including introduction of therapeutically effective amount of antibody to acetyl-CoA-acetyltransferase to the medically indigent patient.EFFECT: invention allows for prevention and treatment of the infection caused by bacteria Clostridium difficile and Enterococcus faecalis, faecium.43 cl, 6 tbl
ethod of preparing diagnostic agglutinating serum for pathogenic yersinia strains // 2358764
FIELD: medicine.SUBSTANCE: method of preparing diagnostic agglutinating serum for pathogenic Yersinia strains involves hyperimmunisation of rabbits with antigen representing 0.4-0.6% formalin inactivated antigen (pYV+) of Yersinia enterocolitica My 03R strain into auricular cranial vein. Immunisation of rabbits with said antigen is fourfold in dosage as follows: 290-310 million kl/ml, 490-510 million kl/ml, 0.99-1.1 billion kl/ml and 1.9-2.1 billion kl/ml, respectively with dosage interval 6-7 days. Further the producer is examined for immunogenic properties. Serum separated from the sampled blood is preserved.EFFECT: method ensures preparation of high-quality agglutinating serum used in yersiniosis diagnostics in animals.3 ex

onoclonal antibody directed against gna33 peptide and its application // 2355704
FIELD: medicine.SUBSTANCE: invention describes monoclonal antibody directed against GNA33 peptide with definite amino acid sequence, which demonstrates complement-mediated bactericidal and/or opsonic activity against bacteria Neisseria meningitides of serogroup B (MenB). On the basis of monoclonal antibody composition for treatment and prevention of MenB disease has been constructed, and application of composition favours production of immune response against said bacteria after its introduction into organism of subject-mammal. According to invention monoclonal antibody can also be used for isolating molecular mimetic of epitope of bacteria Neisseria meningitides of serogroup B (MenB) by antibody contact with supposed mimetic and isolation of formed antibody-mimetic complex.EFFECT: according to invention antibodies and based on them compositions can be efficiently used for prevention of MenB disease, as well as for diagnostics of MenB infection.5 cl, 9 dwg, 6 tbl, 5 ex

Neisseria antigens // 2347813
FIELD: chemistry; biochemistry.SUBSTANCE: invented here are proteins of the meningococcus bacteria Neisseria meningitides (mainly strain B), with immunogenic properties. The proteins have defined amino acid sequences, presented in the description, and are coded with corresponding nucleotide sequences. Description is also given of an antibody, specific to the indicated meningococcus proteins. These proteins, coding their nucleotide sequences, as well as the specific antibody, can be used as an active ingredient in compositions for treating or preventing infection caused by Neisseria meningitides. The presented proteins can be used as antigens for making effective vaccines, immunogenic compositions.EFFECT: obtaining proteins, used as ingredients for making effective vaccines, immunogenic compositions.11 cl, 2 tbl, 104 ex

Antigenes neisseria meningitidis // 2343159
FIELD: medicine; biotechnologies.SUBSTANCE: amino-acid sequences are presented in the list of the sequences obtained from a bacterium, mainly strains A and B which show properties of an antigene. The invention includes corresponding nucleotide sequences of fragments of the nucleinic acid, coding amino-acid sequences of the specified proteins. The proteins under the invention can be used as antigenes for obtaining of specific antibodies and manufacturing of compositions for treatment, preventive maintenance or diagnostics of the infection caused Neisseria meningitidis. The compositions are prepared on the basis of a protein, a fragment of nucleinic acid or an antibody with addition of the pharmaceutically comprehensible carrier and represent vaccinal, diagnostic or pharmaceutical compositions. Sequences of the obtained proteins have no any considerable homology with sequences Neisseria gonorrhoeae, that allows to receive treatment-and-prophylactic and diagnostic compositions with high specificity in relation to N. meningitidis and also to receive Diagnostic reagents for differentiation N. meningitidis from N. gonorrhoeae.EFFECT: efficiency of application.12 cl, 2 tbl, 17 ex

Neisseria meningitidis peptide for therapeutic and diagnostic application // 2313535
FIELD: biotechnology, microbiology, immunology.SUBSTANCE: invention proposes peptide from N. meningitides eliciting a sequence SEQ ID NO:10 that is used in treatment or diagnosis. Also, invention proposes polynucleotide encoding this peptide, a host-cell expressing peptide, microorganism, vaccine and antibody showing specificity to peptide proposed. Invention can be used in medicine.EFFECT: valuable medicinal properties of peptide.16 cl, 2 tbl

Treatment of infection caused by microorganisms // 2303460
FIELD: medicine, immunology, pharmacy.SUBSTANCE: invention relates to antibody, drug based on thereof used in treatment or diagnosis of infection caused by microorganism expressing of the protein GrfA homolog. Also, invention discloses a method for preparing a drug said and a pharmaceutical package used in treatment of the diseases said. The described antibody shows the established amino acid sequence represented as the sequence SEQ ID NO:2 given in the description, and antibody or its antigen-binding fragment that binds specifically with epitope allowing by peptide with amino acid sequence given in SEQ ID NO:3 and disclosed in the description. Using the invention provides enhancing the therapeutic effectiveness of a glycopeptide antibiotic as compared with using a single antibiotic.EFFECT: enhanced effectiveness of infection.22 cl, 1 dwg, 10 tbl
ethod for production of melioidosic immune serum // 2249464
FIELD: microbiology and immunology, in particular immunodiagnosis.SUBSTANCE: atypical strain of melioidose Burkholderia pseudomallei-111-6-1 with altered phenotype defected with respect to synthesis of 8 antigen and acting as immunosuppressor is used as antigen for animal immunization. Immune serum is obtained after 2 immunization cycles of animal-producer with titer in gel immunodiffusion reaction not less than 1:128.EFFECT: immune serum with increased specific activity.2 tbl, 2 ex
 
2551089.
Up!